Преглед Conference Proceeding по датуму издавања
Приказ резултата 1-20 од 78
-
Shikonin derivatives trigger phenotype reprogramming of B16 mouse melanoma cells
(Belgrade: Faculty of Chemistry, 2023) -
In vitro биолошка евалуација аналога di-tert-бутилфенола на бази p-карборана / In vitro biological evaluation of p-carborane-based di-tert-butylphenol analogs
(Kragujevac: Serbian Society for Immunology, Molecular Oncology and Regenerative Medicine, 2023) -
Cisplatin-naproxen conjugate free and loaded in SBA- 15 indicate morphological changes and antitumor activity in vivo in mouse melanoma model
(Belgrade: Faculty of Chemistry, 2023) -
Aнтитуморски потенцијал изонимесулида и његових деривата карборана / Antitumor potential of isonimesulide and its carborane derivatives
(Kragujevac: Serbian Society for Immunology, Molecular Oncology and Regenerative Medicine, 2023) -
Antitumor potential of novel triphenyltin(IV) complexes with carboxylato N-functionalized 2-quinolone ligands
(Belgrade: Faculty of Chemistry, 2023) -
Insights into iridoid biosynthesis in Nepeta species (subfam. Nepetoidae, fam. Lamiaceae): Functional characterization of a key enzyme
(Belgrade: Faculty of Chemistry, 2023) -
Anticancer potential of diiron thiocarbyne complexes
(Belgrade: Faculty of Chemistry, 2023) -
Novosintetisani fluorescentni AhR ligand podstiče povećanje udela T regulatornih ćelija i ublažava kliničku sliku dijabetesa tipa 1 kod C57BL/6 miševa
(Belgrade: Serbian Academy of Sciences and Arts, 2023) -
The effects of cisplatin-ibuprofen conjugate free and immobilized in mesoporous nanostructured silica on the change of morphology of mouse melanoma cells, and antitumor potential in vivo
(Belgrade, Serbia: Serbian Associaton for Cancer Research, 2023) -
Anticancer activity of diphenyltin(IV) compounds bearing carboxylato N-functionalized 2-quinolones
(Belgrade: Serbian Association for Cancer Research, 2023) -
HYCO-3, an Nrf2 activator that simultaneously releases carbon monoxide (CO), ameliorates type 1 diabetes in a mouse model
(BenBedPhar Consortium, 2023) -
Immunomodulatory properties of HYCOs, NRF2 activators that simultaneously release carbon monoxide (CO) to cells and tissues
(BenBedPhar Consortium, 2023) -
Potential of Tamoxifen-based Copper(II) Dichloride in Breast Cancer Therapy
(Belgrade: Serbian Association for Cancer Research, 2023) -
Development of a novel compound that upregulates Treg in the gut by modulating aryl hydrocarbon receptor's activity
(European Federation of Immunological Societies (EFIS), 2023) -
Anoikis as a novel mode of shikonin derivatives anticancer action on C6 glioma cells
(Belgrade: Serbian Association for Cancer Research, 2023) -
Tамоксифен као вектор за платинске(II) и паладијумске(II) комплексе у третману рака дојке / Tamoxifen as a vector for platinum(II) and palladium(II) complexes in breast cancer treatment
(Kragujevac: Serbian Society for Immunology, Molecular Oncology and Regenerative Medicine, 2023) -
Distinct clinical outcomes of Complete Freund’s adjuvant-free experimental autoimmune encephalomyelitis induced in DA rats
(Belgrade: Serbian Neuroscience Society, 2023) -
Nrf2 down-regulation mediates pro-inflammatory effects of novel synthetic AhR ligands
(BenBedPhar Consortium, 2023) -
The effect of diiron thiocarbyne complex on tumor cells of different grade
(Belgrade, Serbia: Serbian Associaton for Cancer Research, 2023) -
Control of IFN-γ Responsiveness and Metastatic Potential in Melanoma by GSTA4
(Belgrade: Serbian Association for Cancer Research, 2023)